AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01658930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple hysterectomy + pelvic lymph node dissection
Description: This procedure may be performed abdominally, laparoscopically, robotically or vaginally. Extrafascial hysterectomy involves removal of the uterus with cervix without adjacent parametria. The uterine arteries are transected medial to the ureters at the level of the isthmus and the uterosacral ligaments are transected at the level of the cervix. Surgeons should pay special attention to make sure that the whole cervix is removed. As such, a maximum of 0.5 cm of vaginal cuff can be removed to ensure the complete removal of the cervix.
Study NCT02723591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Oral Capsule
Study NCT02723591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus immediate release
Description: Oral Capsule
Study NCT02310399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus ABI541 Auditory Brainstem Implant
Description: Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device
Study NCT03786484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999
Description: Phosphodiesterase 10 inhibitor (PDE10i)
Study NCT03618550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)
Study NCT00910390 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Slow freezing
Description: Embryos at different developmental stages will be frozen using a solution that contains propanediol and sucrose, individually placed in high security straws, cooled with a programmator and stored in liquid nitrogen.
Study NCT00910390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIT-Irvine
Description: Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
Study NCT03618550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
Study NCT00910390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vit-Vitrolife
Description: Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
Study NCT02792127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Program for Social Anxiety
Description: This program will be completed from participants' homes using their own computers. This online format is based on a Cognitive Behaviour Therapy framework (CBT) and involves seven modules that ask participants to engage in a variety of thinking exercises and activities.
Study NCT02324322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Training
Description: Exoskeleton Training (100 sessions - 1 hour, 4 - 5 sessions per week for 20 weeks) to enhance functional ambulation for persons with a spinal cord injury. To examine the effectiveness of exoskeleton assisted overground walking to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI.
Study NCT02324322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Biopsies
Description: Needle Biopsies for Quadricep Muscles will be performed to define changes in BMD and Bone structure with intensive exoskeleton assisted walking. This procedure includes having a trained physician make a small skin incision, after numbing the area over the muscle, and then removing a tiny sliver of muscle to study under the microscope. Three separate biopsies for one incision will be obtained. The biopsies will be performed at baseline, 7 days, and after the intervention.~To define changes in biochemical markers of bone metabolism with intensive exoskeleton-assisted walking.
Study NCT02324322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI's will provide accurate assessments of muscle CSA of each lower limb (from above the origin of the iliopsoas to the insertion of the achilles tendon) to determine individual's muscle thigh and shank volume.
Study NCT03618550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
Study NCT01305629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spiritual Self-Schema Therapy
Description: The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the addict schema by proposing the construction of an alternate and competing schema: the spiritual self. This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life.
Study NCT01305629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spiritual Self-Schema Therapy
Description: The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the addict schema by proposing the construction of an alternate and competing schema: the spiritual self. This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life.
Study NCT02691663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral bicarbonate supplementation
Study NCT02691663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00668564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.
Study NCT00668564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days before Transplant Drug Frequency~* 4 Cyclophosphamide Once, given over 2 hours~* 3 Cyclophosphamide Once, given over 2 hours~* 2 Cyclophosphamide Once, given over 2 hours~* 1 Cyclophosphamide Once, given over 2 hours
Study NCT00668564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: Days before Transplant Drug Frequency~12 Campath-1H Once, given over 2 hours~11 Campath-1H Once, given over 2 hours~10 Campath-1H Once, given over 2 hours
Study NCT00668564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Days before Transplant Drug Frequency~9 Busulfan Four times per day~8 Busulfan Four times per day~7 Busulfan Four times per day~6 Busulfan Four times per day
Study NCT02988388 — intervention group
Intervention type: PROCEDURE
Intervention: Lung biopsy/lobectomy
Description: Lung biopsies and lobectomies are not experimental. Participants will undergo a lung biopsy or a lobectomy as part of standard of care.
Study NCT03050684 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: vaginal washing will be not applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
Study NCT03318367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Complete virtual reality education module
Study NCT03729180 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Routine Elective Surgery- In patient or out patient elective surgery
Description: Participants will be undergoing routine planned surgeries.
Study NCT03729180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine Elective Surgery- In patient or out patient elective surgery
Description: Participants will be undergoing routine planned surgeries.
Study NCT03729180 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test for genetic testing
Description: Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.
Study NCT03729180 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test for genetic testing
Description: Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.
Study NCT03729180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Drug-genetic Profile
Description: Profile describing drugs that may be high-risk, those that should be used with caution, or drugs that are favorable to use based on the participants genes.
Study NCT03729180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug-genetic Profile
Description: Profile describing drugs that may be high-risk, those that should be used with caution, or drugs that are favorable to use based on the participants genes.
Study NCT03340350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline capsule
Study NCT03311126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine is a chemotherapeutic agent that has dual functional properties of both an alkylating agent and a nitrogen mustard. Through these unique cytostatic properties, bendamustine is able to inhibit DNA transcription, replication, and repair. Bendamustine is approved in the U.S. for treatment of chronic lymphocytic leukemia (CLL) and for indolent B cell non-Hodgkin lymphomas (NHLs) progressing during or within 6 months of rituximab or a rituximab - containing regimen.
Study NCT03311126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is a glycoengineered, humanized, type II anti-CD20 monoclonal antibody (mAb).
Study NCT04140487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV
Study NCT04140487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given PO
Study NCT04140487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT00374556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3mg placebo capsule, once daily at bedtime
Study NCT00374556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: 3mg capsule, once daily at bedtime
Study NCT04146688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Balance Board
Description: The SSM is measured with an innovative tool (Music Balance Board) developed at the University of Ghent (Belgium) and specially designed to record the movements of the elderly in a natural and comfortable position This chair is equipped with a tablet and sensors that record the movements of the hand and body during the SSM to a musical sequence. The analysis will focus on the difference between the participant's striking and the beat of the music measured using this chair.
Study NCT04426630 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mHealth for heart failure patients in Uganda
Description: Patients at Uganda Heart Institute will be enrolled in an mHealth program intended to promote self-care for heart failure and improve their healthcare quality of life.
Study NCT04049279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BiMobile standard cement
Description: BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
Study NCT04049279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BiMobile larger cement
Description: BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.
Study NCT04049279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Avantage standard cement
Description: Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
Study NCT02502929 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Services
Study NCT02502929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Study NCT02502929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Plus Medication Therapy Management
Study NCT02427165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: A dual PDE3 and PDE4 inhibitor
Study NCT02427165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: a beta-2 receptor agonist
Study NCT02427165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: RPL554 placebo containing no active ingredients
Study NCT02579603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib 150mg bid
Study NCT02579603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Study NCT01929252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 2mcg.kg-1 dexmedetomidine wound infiltration
Study NCT01929252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: 0.25% levobupivacaine (40ml) wound infiltration
Study NCT04036084 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral Magnetic resonance imaging (MRI)
Description: Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Inclusion Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Month 1 Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Year 1
Study NCT00768222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: silk suture
Description: skin closure
Study NCT00768222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VICRYL* Plus suture
Description: skin closure
Study NCT00278629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell transplantation
Description: Autologous hematopoietic stem cell transplantation
Study NCT00203567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbamazepine ER
Description: Active study drug, no comparator
Study NCT02462161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.
Study NCT02462161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will administer placebo two times per day with an intranasal delivery device.
Study NCT00312013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin
Description: Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.
Study NCT02265328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Description: Oral Bovine colostrum 200 ml (20 gram) TDS × 2 months
Study NCT02265328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition
Description: Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.
Study NCT02265328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Oral prednisolone 40mg/day × 4 weeks and tapered to \<40mg/day for next 4 weeks. (If Lilli score > 0.45 after 7 days, then prednisolone would be stopped)
Study NCT04294888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
Study NCT04294888 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
Study NCT02094235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6005 0.05%
Study NCT02094235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 g placebo ointment
Study NCT00762151 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative Control (Regular Toothpaste)
Description: Regular Toothpaste
Study NCT00762151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Control (anti-plaque/anti-bacterial toothpaste)
Description: Standard anti-plaque and anti-bacterial toothpaste
Study NCT00762151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prototype (AN0128 Toothpaste)
Description: AN0128 Toothpaste
Study NCT03560362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Study NCT03560362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine / Epinephrine
Study NCT03874234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3186899
Description: GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.
Study NCT03874234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
Study NCT03874234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
Study NCT01819935 — intervention group
Intervention type: DRUG
Intervention: linezolid (Zyvox)
Description: As prescribed-this is retrospective cohort of existing clinical data.
Study NCT01819935 — intervention group
Intervention type: DRUG
Intervention: vancomycin
Description: As prescribed-this is retrospective cohort of existing clinical data.
Study NCT02303587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study NCT02094235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6005 0.2%
Study NCT01193985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIGR Matrix Surgical Mesh
Description: Lichtenstein repair of inguinal hernia using TIGR Matrix Surgical Mesh
Study NCT04094389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthotic continuous wear group
Description: Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated.